


1	Summary	
	1.1 English	p. 4
	1.2 Russian (Русский)	p. 5
2	Commentary	
	2.1 European Union and West (EU & West)	p. 7
	2.2 Balkans	p. 9
	2.3 East	p. 10
	2.4 TB mortality	p. 12
	2.5 Conclusions & Recommendations	p. 12
	2.6 References	p. 13
3	Tables	
	Summary Table. Tuberculosis surveillance data by area, 2006	p. 15
	Tuberculosis case reporting	
	Table 1 Data format and completeness of tuberculosis reporting, 2006	p. 17
	Table 2 Tuberculosis cases, case rates per 100,000 population and mean annual change in rates, 2002-2006	p. 18
	Table 3 Tuberculosis cases by geographic origin and sex ratio, 2006	p. 19
	Table 4 Tuberculosis cases of national origin, by age group, 2006	p. 20
	Table 5 Tuberculosis cases of foreign origin, by age group, 2006	p. 21
	Table 6 Tuberculosis cases of foreign origin, by area of origin, 2006	p. 22
	Table 7 Tuberculosis cases by geographic origin, 2000-2006	p. 23
	Table 8 Tuberculosis cases by site of disease, 2006	p. 24
	Table 9 Extrapulmonary tuberculosis cases and pulmonary-to-extrapulmonary ratio, 2000-2006	p. 25
	Table 10 TB meningitis or disseminated TB, paediatric and adult cases by origin, 2006	p. 26
	Table 11 TB meningitis, total cases at all ages and cases & rates in children under 5 years, 2002-2006	p. 26
	Table 12 Pulmonary sputum smear positive tuberculosis cases, 2004-2006	p. 27
	Table 13 Tuberculosis cases by history of previous TB treatment, 2001 & 2006	p. 28
	Table 14 Tuberculosis cases confirmed by culture, 2003-2006	p. 29
	Table 15 Tuberculosis cases by <i>M. tuberculosis</i> complex species, 2006	p. 30
	Table 16 Classification of tuberculosis cases according to the European TB case definition (as revised), 2006	p. 31
	Table 17 Tuberculosis cases with HIV infection, 2000-2006	p. 32
	Table 18 AIDS cases with tuberculosis as initial AIDS indicative disease, 2006	p. 33
	Table 19 AIDS cases with tuberculosis as initial AIDS indicative disease, 2000-2006	p. 34
	Anti-tuberculosis drug resistance	
	Table 20 Multidrug resistance (MDR) by previous history of TB treatment, latest available data	p. 35
	Table 21 Laboratory practices and quality assurance for anti-TB Drug Susceptibility Testing (DST), 2006	p. 36
	Table 22 Characteristics of anti-TB drug resistance surveillance, 2006	p. 37
	Table 23 Anti-TB drug resistance, all tuberculosis cases (combined resistance), 2006	p. 38
	Table 24 Anti-TB drug resistance, previously untreated tuberculosis cases (primary resistance), 2006	p. 39
	Table 25 Combined anti-TB drug resistance, tuberculosis cases of national origin, 2006	p. 40
	Table 26 Combined anti-TB drug resistance, tuberculosis cases of foreign origin, 2006	p. 41
	Table 27 Combined multidrug resistance (MDR) by geographic origin, 2001-2006	p. 42
	Treatment outcome and mortality	
	Table 28 Characteristics of treatment outcome monitoring (TOM) and treatment success, 2005	p. 43
	Table 29 Treatment outcome, new definite pulmonary tuberculosis cases, 2005	p. 44
	Table 30 Treatment outcome, retreated definite pulmonary tuberculosis cases, 2005	p. 45
	Table 31 Treatment outcome by geographic origin, all pulmonary cases, 2005	p. 46
	Table 32 Treatment outcome by site of disease, 2005	p. 47
	Table 33 Tuberculosis deaths by localisation of disease, latest available year	p. 48
	Table 34 Tuberculosis deaths and mortality rates, 2000-2005	p. 49
4	Maps & Figures	
	Map 1 Total tuberculosis notifications, 2006	p. 51
	Map 2 Total tuberculosis notification rates, 2006	p. 51
	Map 3 Tuberculosis mortality rates, 2001-2006	p. 52
	Map 4 Tuberculosis cases of foreign origin, 2006	p. 52
	Map 5 Tuberculosis cases not previously treated, 2006	p. 53
	Map 6 Tuberculosis cases confirmed by culture, 2006	p. 53
	Map 7 Tuberculosis cases with primary multidrug resistance (primary MDR), 2006	p. 54
	Map 8 Case-based reporting to EuroTB in 2007	p. 54
	Figure 1 Total TB notifications (by previous treatment history) and total TB case rates, 2001-2006	p. 55
	Figure 2 Tuberculosis cases by geographic origin, EU & West, 2000-2006	p. 56
	Figure 3 Treatment outcome by area, previously untreated definite pulmonary TB cases, 2001-2005	p. 56
5	Country Profiles	p. 57
6	Technical Note	p. 111

SURVEILLANCE OF TUBERCULOSIS IN EUROPE

Report on tuberculosis cases notified in 2006



EuroTB



WHO Collaborating Centre for the
Surveillance of Tuberculosis in Europe



EuroTB national Contact Points and participating institutions (2007)

Country	Contact Points	Institution
Andorra	M. Coll Armangué	Ministry of Health and Welfare, Andorra la Vella
Albania	H. Hafizi	University Hospital of Lung Diseases, Tirana
Armenia	V. Pogosian	Ministry of Health, Yerevan
Austria	J.-P Klein	Federal Ministry for Health and Women, Vienna
Azerbaijan	F. Agaev	Scientific Research Institute for Lung Diseases, Baku
Belarus	H. Gurevich	Institute of Lung Diseases and Tuberculosis, Minsk
Belgium	M. Wanlin, G. Vankersschaever	Belgium Lung & Tuberculosis Association (BELTA), Brussels
Bosnia & Herzegovina	Z. Dizdarevic	Clinic of Pulmonary Diseases and Tuberculosis "Podhrastovi", Sarajevo
	M. Duronjic	Ministry of Health and Social Security, Banja Luka
Bulgaria	V. Milanov	Public Health Directorate, Ministry of Health, Sofia
Croatia	A. Simunovic	Croatian National Institute of Public Health, Zagreb
Cyprus	C. Hadjianastassiou	Chest Clinic, Nicosia General Hospital, Nicosia
Czech Republic	J. Wallenfels	National Tuberculosis Surveillance Unit, Prague
Denmark	P. Andersen	Statens Serum Institute, Copenhagen
Estonia	V. Hollo	Estonian National TB Register, Tallinn
Finland	P. Ruutu	National Public Health Institute, Helsinki
France	D. Antoine, D. Che	Institut de Veille Sanitaire, Saint-Maurice
Georgia	A. Salakaia	National Centre for Tuberculosis and Lung Diseases, Tbilisi
Germany	B. Brodhun, W. Haas	Robert Koch-Institut, Berlin
Greece	G. Spala	National Centre for Surveillance and Intervention (NCSI), Athens
Hungary	J. Strausz	"Koranyi" National Institute of TB & Lung Disease, Budapest
Iceland	T. Blöndal	Health Care Services, Department of TB and Lung Diseases, Reykjavik
Ireland	J. O'Donnell	HSE Health Protection Surveillance Centre, Dublin
Israel	D. Chemtob	Ministry of Health, Jerusalem
Italy	M.G. Pompa	Ministry of Health, Rome
Kazakhstan	S.S. Ismailov	National Centre for TB Problems, Ministry of Public Health, Almaty
Kyrgyzstan	A.S. Alisherov	National Tuberculosis & Lung Diseases Institute, Bishkek
Latvia	J. Leimans	State Centre of Tuberculosis & Lung Diseases of Latvia, Riga
Lithuania	E. Davidaviciené	Lithuanian Centre of Lung Diseases & Tuberculosis, Vilnius
Luxembourg	P. Huberty-Krau	Directorate General of Health, Luxembourg
Macedonia, FYR	A. Vidoevska, S. Talevski	Institute for Lung Diseases and Tuberculosis, Skopje
Malta	A. Pace Asciak	Department of Public Health, Qormi
Moldova, Republic of*	D. Sain, S. Sofronie	Institute of TB and Lung Diseases, Chisinau
Monaco	A. Nègre	Direction de l'Action Sanitaire et Sociale, Monaco
Montenegro	O. Bojovic	Hospital for Lung Diseases and TB, Niksic
Netherlands	C. Erkens	KNCV Tuberculosis Foundation, The Hague
Norway	B. Winje-Askeland	National Tuberculosis Register, Oslo
Poland	M. Korzeniewska-Kosela	National Institute of Tuberculosis & Lung Diseases, Warsaw
Portugal	A. Fonseca Antunes	Ministry of Health, Directorate General of Health, Lisbon
Romania	D.I. Chiotan, E. Ibraim	Pneumology Institute "Marius Nasta" UIP, Bucharest
Russian Federation	E.P. Kakorina	Federal Ministry of Health and Social Development, Moscow
San Marino	A. Sorcinelli	State Hospital of San Marino, Cailungo
Serbia	G. Radosavljevic-Asic	Institute for Lung Diseases and Tuberculosis, Belgrade
Slovakia	I. Solovic	Institute for TB, Respiratory Diseases & Thoracic Surgery, Vysné Hagy
Slovenia	D. Erzen	University Clinic of Respiratory and Allergic Diseases, Golnik
Spain	E. Rodriguez Valin	Institute of Health "Carlos III", Madrid
Sweden	V. Romanus	Swedish Institute for Infectious Disease Control, Solna
Switzerland	P. Helbling	Swiss Federal Office of Public Health, Bern
Tajikistan	S.M. Saidaliev	Republican Tuberculosis Centre, Dushanbe
Turkey	F. Gümüslü	Ministry of Health, Ankara
Turkmenistan	B.D. Jumaev	Central Hospital for Tuberculosis, Ashgabat
Ukraine	M. Golubchikov	Centre of Medical Statistics, Ministry of Health, Kiev
United Kingdom	J. Watson	Health Protection Agency, London
	J. McMenamin	Health Protection Scotland, Glasgow
	R. Salmon	National Public Health Service, CDSC, Cardiff, Wales
	B. Smyth	Communicable Disease Surveillance Centre, Belfast, Northern Ireland
Uzbekistan	D. Ulmasova	Republican Tuberculosis DOTS Centre, Ministry of Health, Tashkent

* referred to as Moldova in this report

The EuroTB project was set up in 1996 to develop and coordinate a European network of national tuberculosis surveillance institutions in the 53 countries of the WHO European Region. The project was based at the Institut de veille sanitaire (InVS), France, and was financially supported by the European Commission (DG-SANCO) until the end of 2007. The mission statement of EuroTB was to improve the contribution of surveillance to tuberculosis control in the WHO European Region.

A central activity of EuroTB was the collection and validation of national epidemiological information on tuberculosis. The most recent data are presented in this report. The EuroTB reports and other material are available on www.eurotb.org.

The suggested citation for this report is the following:

i) English

EuroTB and the national coordinators for tuberculosis surveillance in the WHO European Region. Surveillance of tuberculosis in Europe. Report on tuberculosis cases notified in 2006, Institut de veille sanitaire, Saint-Maurice, France. March 2008.
--

ii) Russian (Русский)

ЕвроТБ и национальные координаторы по эпиднадзору за туберкулезом в Европейском регионе ВОЗ. Эпиднадзор за туберкулезом в Европе. Отчёт о случаях туберкулеза зарегистрированных в 2006 г. Институт общественного здравоохранения и эпидемиологического надзора, Сен Морис, Франция. Март 2008 г.

The staff of EuroTB in 2007

Fatima Ait-Belghiti	epidemiologist
Hedwige Bousquié	assistant
Isabelle Devaux	epidemiologist
Dennis Falzon	coordinator
Yao Kudjawu	epidemiologist

Acknowledgments

This report was prepared by EuroTB staff. Jean-Claude Desenclos and Vanina Bousquet of the Institut de veille sanitaire also helped in its finalization. Collection and validation of aggregate data on TB case notification, drug resistance and treatment outcome monitoring were done jointly with TB control staff at the WHO-Regional Office for Europe (Andrei Dadu) and at the WHO-Headquarters (Katherine Floyd, Mehran Hosseini, Abigail Wright). The European AIDS reporting data set (ENAADS), which includes data on tuberculosis as initial AIDS indicative disease, was provided by the project "Surveillance of HIV/AIDS in Europe" (EuroHIV). The Advisory Committee of EuroTB has provided support and advice on surveillance activities. Members in 2007 were: Luke Clancy (UNION), Francis Drobniowski (United Kingdom), Michael Forssbohm (Germany), Elmira Ibraim (Romania), Jean-Paul Klein (Austria), Maria Korzeniewska-Kosela (Poland), Vincent Kuyvenhoven (KNCV), Petri Ruutu (Finland), John Watson (United Kingdom), and Richard Zaleskis (WHO/EURO). The European Centre for Disease Prevention and Control (ECDC) was represented at Committee meetings since 2006 by Karoline Fernandez de la Hoz.

Neither the European Commission nor any person acting on behalf of the Commission is liable for the use that may be made of the information contained in this report. Maps and commentary used in this report do not imply any opinion whatsoever of EuroTB or its partners on the legal status of the countries and territories shown or concerning their borders.